{"id":645525,"date":"2023-04-04T21:36:02","date_gmt":"2023-04-04T21:36:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=645525"},"modified":"2023-04-04T21:36:02","modified_gmt":"2023-04-04T21:36:02","slug":"creative-biomart-released-intravenous-immunoglobulin-product-for-research-use","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/creative-biomart-released-intravenous-immunoglobulin-product-for-research-use_645525.html","title":{"rendered":"Creative BioMart Released Intravenous Immunoglobulin Product for Research Use"},"content":{"rendered":"
\"Creative<\/a><\/div>\n

Creative BioMart Therapeutic Proteins, a sub-brand of Creative BioMart that provides high-quality products and services to accelerate drug development process, now offers Intravenous immunoglobulin<\/a> (IVIg) for research use need.<\/p>\n

People who lack antibodies can receive treatment with intravenous immune globulin (IVIG). It is made from an assortment of immunoglobulins (antibodies) culled from the plasma of thousands of healthy donors. To combat infection, healthy individuals’ immune systems produce immunoglobulins. While IVIG is made from plasma, a blood product, the likelihood of contracting a bloodborne infection is very low because IVIG has undergone extensive purification.<\/p>\n

Intravenous immunoglobulin is the treatment of choice for patients with antibody deficiencies. It can be used in the treatment of several different conditions, including: Myositis, Lupus, Adult-onset still’s disease, Systemic juvenile idiopathic arthritis, Vasculitis, Antiphospholipid syndrome and People with certain complications of Sjögren’s syndrome.<\/p>\n

As a world-renowned provider of therapeutic proteins<\/a>, Creative BioMart Therapeutic Proteins offers a wide range of raw materials, recombinant protein design, stable cell line development, protein production and purification, protein analysis, and other products and services. In its IVIg, IgG antibody subclasses are distributed similarly to how they are in the general human population. The proportions of each IgG subclass are as follows: 70.3% IgG1, 24.7% IgG2, 3.1% IgG3, and 1.9% IgG4.<\/p>\n

Brief introduction about the Intravenous Immunoglobulin Product at Creative BioMart Therapeutic Proteins:<\/p>\n

Cat# <\/strong><\/p>\n

THP-0108<\/p>\n

Product Name<\/strong><\/p>\n

Intravenous immunoglobulin (IVIg<\/a>)<\/p>\n

Species<\/strong><\/p>\n

Human<\/p>\n

Molecular Weight<\/strong><\/p>\n

142682.3 Da<\/p>\n

Cas No.<\/strong><\/p>\n

9007-83-4<\/p>\n

Formula<\/strong><\/p>\n

C6332H9826N1692O1980S42<\/p>\n

Endotoxin Level<\/strong><\/p>\n

Biological Activity<\/strong><\/p>\n

50mg\/ml<\/p>\n

“As the demanded volume of such products increases constantly, we responded to the needs of biopharmaceutical manufacturers to realize economies of scale. In addition to outstanding capacities, our cutting-edge technology also guarantees high purity and potency as excellent raw materials for the pharmaceutical industry.” Commented Linna, the chief marketing staff at Creative BioMart.<\/p>\n

To know more details about the Intravenous immunoglobulin (IVIg) offered by Creative BioMart Therapeutic Proteins, please visit https:\/\/therapeutic.creativebiomart.net\/intravenous-immunoglobulin-ivig.html<\/a>.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Creative BioMart<\/a>
Contact Person:<\/strong> Caroline
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 1-631-619-7922
Address:<\/strong>45-1 Ramsey Road
City:<\/strong> Shirley
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/therapeutic.creativebiomart.net\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Creative BioMart Therapeutic Proteins, a sub-brand of Creative BioMart that provides high-quality products and services to accelerate drug development process, now offers Intravenous immunoglobulin (IVIg) for research use need. People who lack antibodies can receive treatment with intravenous immune globulin … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,420,416],"tags":[],"class_list":["post-645525","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/645525","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=645525"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/645525\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=645525"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=645525"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=645525"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}